This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Clinical Study of AK112 for NSCLC Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05184712
Recruitment Status : Recruiting
First Posted : January 11, 2022
Last Update Posted : April 12, 2024
Sponsor:
Collaborator:
Akeso
Information provided by (Responsible Party):
Summit Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of Ivonescimab (SMT112 or AK112) or Placebo Plus Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)

Condition or disease Intervention/treatment Phase
Non-Squamous Non-small Cell Lung Cancer Drug: Ivonescimab (SMT112 or AK112) Injection Drug: Placebo Injection Phase 3

Detailed Description:
The trial will be performed as a randomized, Double-Blind, Multicenter trial to compare Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin to Placebo Plus Pemetrexed and Carboplatin in Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring. Approximately 470 subjects will be randomized to two treatment arms at the ratio of 1:1. Each enrolled subject will receive an intravenous infusion of Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin or Placebo Plus Pemetrexed and Carboplatin（Q3W, up to 4 cycles) in treatment periods per the randomization schedule. Afterward, Ivonescimab (SMT112 or AK112) Plus Pemetrexed or Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 470 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Actual Study Start Date : January 1, 2022
Estimated Primary Completion Date : January 1, 2025
Estimated Study Completion Date : January 1, 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Ivonescimab (SMT112 or AK112) in combination with Pemetrexed and Carboplatin
Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
 Drug: Ivonescimab (SMT112 or AK112) Injection
Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, Ivonescimab (SMT112 or AK112) Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
Other Names:
  • Pemetrexed
  • Carboplatin
Placebo Comparator: Placebo in combination with Pemetrexed and Carboplatin
Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
 Drug: Placebo Injection
Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
Other Names:
  • Pemetrexed
  • Carboplatin


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Up to 2 years ]
    Progression-free survival (PFS) assessed by IRC per RECIST v1.1 in the ITT population.

  2. Overall Survival (OS) [ Time Frame: Up to 2 years ]
    Overall Survival (OS) in the ITT population


Secondary Outcome Measures :
  1. ORR [ Time Frame: Up to 2 years ]
    Efficacy measures such as overall response rate (ORR), which is the proportion of subjects with CR or PR by IRRC based on RECIST v1.1

  2. DCR [ Time Frame: Up to 2 years ]
    Disease control rate (DCR), which is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1

  3. DoR [ Time Frame: Up to 2 years ]
    Duration of response (DoR), which is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.

  4. TTR [ Time Frame: Up to 2 years ]
    TTR is defined as the time to response base on RECIST v1.1

  5. PFS [ Time Frame: Up to 2 years ]
    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first assessed by investigator Per RECIST 1.1.

  6. AE [ Time Frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first,up to 2 years ]
    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and clinically significant abnormal laboratory results.

  7. Observed concentrations of AK112 [ Time Frame: through study completion, an average of 2 year ]
    The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration

  8. Number of subjects who develop detectable anti-drug antibodies (ADAs) [ Time Frame: From first dose of AK112 through 90 days after last dose of AK112,up to 2 years ]
    The immunogenicity of AK112 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
  2. Males or females aged ≥ 18 years at the time of signing informed consent.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
  4. Life expectancy ≥3 months；
  5. Locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC confirmed by histology or cytology, inoperable and unable to receive radiotherapy and chemotherapy;
  6. The tumor histology, cytology or hematology confirmed the presence of EGFR activating mutations before enrollment
  7. Have previously received 3rd generation EGFR-TKI treatment and have progressed on or following
  8. Subjects have at least one measurable non-brain tumor lesion per RECIST v1.1
  9. Major organ function prior to treatment meets the following criteria
  10. Patients of childbearing potential must agree to use effective contraceptive measures

Exclusion Criteria:

  1. Histological or cytological pathology confirmed the presence of small cell carcinoma components, or the main component is squamous cell carcinoma
  2. There are reports confirming the existence of other driver gene mutations with known drug treatments
  3. Subjects who received any prior treatments targeting the mechanism of tumor immunity
  4. The subject has received systemic anti-tumor therapy other than EGFR-TKI
  5. Currently enrolled in any other clinical study
  6. Received EGFR-TKI treatment, palliative local treatment, non-specific immunomodulatory treatment within 2 weeks prior to the first dose.
  7. Tumor surrounds important blood vessels or has obvious necrosis, cavitation, or invades surrounding important organs and blood vessels.
  8. Symptomatic central nervous system metastases
  9. Active malignancies within the past 3 years, with the exception of tumors in this study and cured local tumors
  10. Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment
  11. There is a history of major diseases 1 year prior to the first dose.
  12. .Medical history of gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose
  13. Received chest radiation therapy prior to the first dose
  14. Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
  15. Active or previously documented inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05184712


Contacts
Layout table for location contacts
Contact: Lori Styles, MD 1-833-256-0522 medicalinformation@smmttx.com

Locations
Show Show 64 study locations
Sponsors and Collaborators
Summit Therapeutics
Akeso
Investigators
Layout table for investigator information
Principal Investigator: Li Zhang, MD Sun Yat-sen University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Summit Therapeutics
ClinicalTrials.gov Identifier: NCT05184712    
Other Study ID Numbers: AK112-301
HARMONi ( Other Identifier: Summit Therapeutics )
First Posted: January 11, 2022    Key Record Dates
Last Update Posted: April 12, 2024
Last Verified: April 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
 Respiratory Tract Diseases
Carboplatin
Pemetrexed
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors